

Nishitha Reddy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5296048/publications.pdf>

Version: 2024-02-01

41
papers

1,412
citations

687363

13
h-index

377865

34
g-index

41
all docs

41
docs citations

41
times ranked

3317
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.. Journal of Clinical Oncology, 2022, 40, 7511-7511. | 1.6 | 4 |
| 2 | Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood, 2021, 137, 374-386. | 1.4 | 59 |
| 3 | Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica, 2021, 106, 1932-1942. | 3.5 | 21 |
| 4 | Exploiting Tumor Necrosis Factor Aberrations in Marginal Zone Lymphoma. JCO Precision Oncology, 2021, 5, 569-573. | 3.0 | 1 |
| 5 | Burkitt Lymphoma International Prognostic Index. Journal of Clinical Oncology, 2021, 39, 1129-1138. | 1.6 | 37 |
| 6 | Initial results of the combination of PI3KÎ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.. Journal of Clinical Oncology, 2021, 39, 7553-7553. | 1.6 | 1 |
| 7 | Efficacy and safety of the PI3KÎ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24).. Journal of Clinical Oncology, 2021, 39, 7550-7550. | 1.6 | 3 |
| 8 | How we treat advanced stage cutaneous Tâ€cell lymphoma â€“ mycosis fungoides and SÃ©zary syndrome. British Journal of Haematology, 2021, 195, 352-364. | 2.5 | 10 |
| 9 | HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Advances, 2021, 5, 2852-2862. | 5.2 | 24 |
| 10 | Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study. Blood, 2021, 138, 1365-1365. | 1.4 | 8 |
| 11 | Tolerability and durable responses of the PI3KÎ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.. Journal of Clinical Oncology, 2020, 38, 8016-8016. | 1.6 | 8 |
| 12 | Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites.. Journal of Clinical Oncology, 2020, 38, 8043-8043. | 1.6 | 0 |
| 13 | A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma. Blood, 2020, 136, 8-10. | 1.4 | 1 |
| 14 | Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. Blood, 2020, 136, 24-26. | 1.4 | 0 |
| 15 | Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. Blood, 2020, 136, 49-50. | 1.4 | 1 |
| 16 | EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. Blood, 2020, 136, 4-6. | 1.4 | 0 |
| 17 | The Burkitt Lymphoma International Prognostic Index (BL-IPI). Blood, 2020, 136, 46-49. | 1.4 | 0 |
| 18 | Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. Blood, 2020, 136, 35-36. | 1.4 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715. | 7.1 | 44 |
| 20 | Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946. | 1.3 | 3 |
| 21 | Safety of Mogamulizumab in Mycosis Fungoides and SÅ©zary Syndrome: Final Results from the Phase 3 Mavoric Study. <i>Blood</i> , 2019, 134, 5300-5300. | 1.4 | 3 |
| 22 | The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019, 134, 397-397. | 1.4 | 3 |
| 23 | Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402. | 1.4 | 9 |
| 24 | Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study. <i>Blood</i> , 2019, 134, 2817-2817. | 1.4 | 1 |
| 25 | Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. <i>Blood</i> , 2019, 134, 19-19. | 1.4 | 4 |
| 26 | Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. <i>Blood</i> , 2019, 134, 1554-1554. | 1.4 | 0 |
| 27 | Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kÎ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies. <i>Blood</i> , 2018, 132, 2893-2893. | 1.4 | 13 |
| 28 | Genetic and Functional Drivers of Diffuse Large BÂCell Lymphoma. <i>Cell</i> , 2017, 171, 481-494.e15. | 28.9 | 804 |
| 29 | A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. <i>Blood</i> , 2017, 130, 1676-1679. | 1.4 | 26 |
| 30 | Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248. | 2.5 | 115 |
| 31 | MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 154-154. | 1.4 | 1 |
| 32 | Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 385-391. | 0.4 | 35 |
| 33 | Superior Long-Term Outcome of Patients With Early Transformation of Non-Hodgkin Lymphoma Undergoing Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 406-411. | 0.4 | 19 |
| 34 | Consolidative therapy with stem cell transplantation improves survival ofÂpatients with mantle cell lymphoma after any induction regimen. <i>Experimental Hematology</i> , 2012, 40, 359-366. | 0.4 | 8 |
| 35 | Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 591-597. | 2.0 | 82 |
| 36 | Treatment Options for Transformed Lymphoma: Incorporating Allogeneic Stem Cell Transplantation in a Multimodality Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1265-1272. | 2.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Hodgkin's Lymphoma: Richter's Transformation of Chronic Lymphocytic Leukemia Involving the Liver. Journal of Clinical Oncology, 2010, 28, e543-e544. | 1.6 | 11 |
| 38 | Primary bone lymphoma: a set of unique problems in management. Leukemia and Lymphoma, 2010, 51, 1-2. | 1.3 | 16 |
| 39 | SNX 2112, An Oral Hsp-90 Inhibitor Exerts Antiproliferative Effects in Combination with Bortezomib and Rituximab in Rituximab Resistant Non-Hodgkin's Lymphoma.. Blood, 2009, 114, 3733-3733. | 1.4 | 2 |
| 40 | A High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Is Obesity a Risk Factor for APL? Implication of Targeted Therapy to Control Obesity and APL Prevention.. Blood, 2009, 114, 3099-3099. | 1.4 | 0 |
| 41 | Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome.. Blood, 2009, 114, 3407-3407. | 1.4 | 0 |